Novavax charges ahead with $200M in fresh capital

Novavax Inc. plans to progress its Covid-19 vaccine candidate with new additions to the company and about $200 million from selling convertible preferred stock to an RA Capital Management investment fund — the latest cash infusion for the Montgomery County vaccine maker. The preferred private placement with the Boston firm, which closed June 16, came less than two weeks after Novavax (NASDAQ: NVAX) won a Department of Defense contract worth up to $60 million to help manufacture its coronavirus…